Breaking News, Financial News

Financial Report: Alexion

Soliris sales up 24% in the quarter

Alexion

2Q Revenues: $636.2 million (+24%)

2Q Earnings: $170.2 million (+2%)

YTD Revenue: $1.2 billion (+15%)

YTD Earnings: $261.5 million (-20%)

Comments: Solirissales were $636 million in the quarter, up 24%. R&D expenses were $131.7 million compared to $92.6 million in 2Q14. The company closed the Synageva acquisition in the quarter, strengthening its rare diseases portfolio. Strensiq received a positive opinion from the EMA recommending marketing authorization for the long-term enzyme replacement therapy in patients with pediatric-onset HPP. Kanuma also receiveda positive EMA opinion recommending marketing authorization for long-term enzyme replacement therapy in patients of all ages with lysosomal acid lipase deficiency.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters